Discovering breakthroughs in fibrosis and neurodegeneration

Blade Clinical Trials

Today, we are advancing a robust pipeline of potential first-in-class, oral, small-molecule therapies for diseases that result from protein deposition (fibrosis) or protein aggregation (neurodegeneration) that disrupt normal cellular, tissue or organ function. This pipeline includes an autotaxin inhibitor and multiple inhibitors of dimeric calpains to treat lung, liver and cardiac fibrosis or neurodegenerative diseases.

Find Clinical Trials Near Me

Program Indication Study Phase Status Trial number
BLD-0409 Healthy Volunteer Safety Testing Phase 1 Complete NCT04146805
BLD-0409-102 Relative Bioavailability Phase 1b In Process NCT04814472
BLD-0409-103 Drug-Drug Interaction Phase 1b In Process NCT04814498
BLD-0409-104 Drug-Drug Interaction with IPF Standard of Care Therapies Phase 1b Planned  
BLD-0409-203 Idiopathic Pulmonary Fibrosis Phase 2 Planned